RETATRUTIDE 10 mg

Retatrutide (10mg) – Next-Generation Triple Agonist

Investigate multi-receptor metabolic pathways with Retatrutide, a novel triple-agonist peptide designed for research into its targeted activity at the GIP, GLP-1, and glucagon receptors. It is evaluated for its comprehensive influence on metabolic regulation, energy expenditure, and glucose homeostasis.

Key Benefits:

• Triple-Receptor Activation: Simultaneously engages GIP, GLP-1, and Glucagon receptors for amplified metabolic signaling.
• Supports Weight & Appetite Regulation: Evaluated for suppression of hunger signals and potential fat mass reduction.
• Promotes Metabolic Rate: Glucagon receptor activity aids in increasing energy expenditure and lipolysis.
• Glucose Homeostasis: Enhances glycemic control and insulin sensitivity.

Ideal For:

• Advanced metabolic rate research
• Weight loss and appetite signaling studies
• Glucose regulation and insulin resistance modeling
• Multi-pathway endocrine investigations

Typical research dosing ranges from 2 mg to 12 mg per week (administered once weekly).

Add 1mL of bacteriostatic water to get a solution that is 10mg/mL, such that every 0.1mL (10 units on an insulin syringe) is equal to 1mg of Retatrutide.

Store unmixed vials in a cool, dark place away from direct light. Once reconstituted, this product must be refrigerated between 2°C – 8°C (36°F – 46°F) and used within 30 days.